MR imaging has been used for diagnosing prostate cancer since the early 1980s. The first reports claimed that prostate cancer could be seen as focal areas of high signal intensity on T2-weighted images. These investigators used mid-and low-field strength magnets and body coils, and their impression was probably coloured by the great enthusiasm for this exciting new technique. In the mid-1980s, when high-field strength T2-weighted MR imaging could show the prostate zonal anatomy using body coil, it was realised that most prostate cancers present as low-intensity lesions within the bright peripheral zone. During the late 1980s, several investigators evaluated the ability of MR imaging in staging known prostate cancer. Despite the use of body coils, the results were surprisingly optimistic, giving accuracies in the range of about 80-90%. In the early 1990s, optimism turned into disappointment, as several (more realistic?) reports appeared showing a rather low accuracy for body coil MR imaging in depicting extracapsular tumour extension.
The introduction of pelvic surface coils and especially endorectal coils has provided a substantial increase in the image quality with respect to signal-to-noise ratio and spatial resolution. The final diagnosis of prostate cancer is today often provided by biopsies guided by transrectal ultrasound. The main role of endorectal coil prostatic MR imaging is local staging of known prostate cancers, i.e. locating the tumour and assessing tumour size, extracapsular growth and invasion of the seminal vesicles. In this setting, any focal lowintensity lesion in the peripheral zone is likely to be called cancer. In a population of patients with prostate cancer, the sensitivity of detecting tumours larger than 5 mm is high (some say close to 100%), and one might consider this non-invasive technique as an alternative primary diagnostic tool.
Screening for cancer is an entirely different matter than locating known cancers, however. The test 347 must provide a diagnosis of cancer or no cancer with high sensitivity and high specificity. In addition to cancer, several other prostatic disorders are common, and various disorders such as benign hyperplasia, cancer and prostatitis, may coexist. A diagnostic test must therefore be able to differentiate cancer from these other disorders and from normal variants as well. This problem complex has been elucidated in an exemplary manner by Dr. S I et al. in a report presented in this issue of Acta Radiologica. Endorectal coil MR imaging was performed on 72 patients, each of which belonged to one of the following groups: Prostate cancer, benign prostatic hyperplasia, acute bacterial prostatitis, chronic bacterial prostatitis, chronic non-bacterial prostatitis/chronic pelvic pain syndrome, or asymptomatic volunteers. The images were read randomly without knowledge of clinical data or patient age, and a total of 20 diagnostic criteria were assessed in the evaluation of the prostate and seminal vesicles. In this blinded setting, the sensitivity in diagnosing cancer was only 50%; the specificity was 83%. The criteria commonly used for diagnosing cancer could be found in the most of the other patient groups as well, and no single criterion was clearly better than the others in diagnosing cancer.
The study by Dr. S I et al. shows that MR imaging at the present stage of development is unsuitable as a primary diagnostic tool for prostate cancer. In a wider sense, it also illustrates the need for radiology to perform in a clinical environment. Some referring clinicians seem to believe that the radiologist should know as little as possible about clinical history or findings to avoid bias in the interpretation of findings. Nothing could be more wrong. Radiology is no more an exact science than other medical specialties, and a thorough clinical knowledge is often a prerequisite for providing a helpful differential diagnosis.
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